The Company's broad, versatile technology has been researched in the scientific laboratory for over eleven years. Over eleven million US dollars have been invested in its development. Infused capital is primarily from National Institutes of Health grants and private investments. The research resulted in the issuance of patents to protect the technology. In addition, there have been over fifty peer-reviewed publications demonstrating the safety, efficacy and production of the technology in animal studies. This proof-of-concept in animals has set the stage to broaden the target disease horizon and begin the corporate approach to clinical trials.
Etubics Corporation's vector vaccines and other products may be incorporated into a broad range of research and clinical applications. Since safety is a critical issue in the use of vector vaccine technology, the Company's scientists have worked diligently to solve this issue and they have succeeded in animal studies. The Company's vector vaccines also have a larger capacity for DNA than competing technologies, which means that they can accommodate a larger payload of protective antigens. In addition, the Company's patented production processes enable large quantities of vector vaccines to be produced at one time, resulting in administration of homogeneous product throughout a clinical application. Etubics Corporation will initially focus on the development, clinical trials, production, and marketing of vector vaccines for the following diseases:
- Bioterrorism targets
- Malaria
- Human Immunodeficiency Virus (HIV)
- Certain cancers
- Leishmania
- Influenza
It is with great pleasure that the business and scientific leaders of Etubics Corporation present its widely protected and much needed products to the medical, business, and investment communities.
Corporate Mission: Etubics Corporation is researching, developing, and will sell next generation vector vaccines to immunize and treat large worldwide populations exposed to or having difficult to treat diseases.